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OBJECTIVES: Pituitary-dependent hyperadrenocorticism is the most common cause of naturally occurring hyper-
cortisolism in dogs. CRHR1 expression in human and dog corticotrophinomas suggested that this gene affects
pituitary tumorigenesis. The present study aimed to investigate mutations in the CRHR1 coding region in
poodles with pituitary-dependent hyperadrenocorticism.
METHODS: Fifty poodles with pituitary-dependent hyperadrenocorticism and 50 healthy poodles were studied.
Genomic DNA was amplified by PCR and analyzed by Sanger sequencing.
RESULTS: The novel CRHR1 p.V97M mutation was identified in one dog. This valine residue, located in the amino-
terminal extracellular domain, exhibits high affinity for its corticotropin-releasing hormone (CRH) ligand.
Bioinformatic analysis revealed structural rearrangements in the mutant protein, with a 17% increase in the
surface binding affinity between CRHR1 and CRH. In vitro functional studies showed that mutant CRHR1
induced higher ACTH secretion than the wild type after stimulation with human CRH.
CONCLUSION: These results suggest that germline activating mutations in CRHR1 may be a rare cause of
pituitary hyperadrenocorticism in poodles.
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’ INTRODUCTION
Cushing’s disease is a common endocrinopathy in dogs
and is characterized by polydipsia, polyuria, polyphagia,
abdominal enlargement and alopecia (1-3). Pituitary-dependent
hyperadrenocorticism (PDH) is the most common cause of
naturally occurring hypercortisolism in dogs, accounting
for 80 to 85% of all cases. PDH mainly affects dogs aged
6 years and older, and poodles, dachshunds, shih tzus and
various terrier breeds appear to be at the greatest risk (4, 5).
More than 90% of dogs with PDH have pituitary tumors,
most of which are microadenomas (o10 mm in diameter) (1, 3).
The secretion of ACTH is mainly controlled by cortico-
tropin-releasing hormone (CRH), which binds to its receptor
CRHR1 and activates the transcription of proopiomelanocortin
(POMC) to release ACTH. The expression of these factors is
regulated by glucocorticoids. Other hypothalamic compounds,
such as vasopressin, can also stimulate ACTH release but with
much lower potency (6).
The finding that CRHR1 is expressed in corticotroph
adenoma cells suggests that this receptor might play a role in
pituitary tumorigenesis. Human patients with Cushing’s
disease exhibit ACTH hypersecretion in response to a CRH
stimulation test, despite the autonomous secretion of ACTH
(7, 8). Similarly, in vitro studies have shown that adenoma-
tous corticotroph cells exhibit a dose-dependent increase in
ACTH levels after CRH stimulation (9, 10). Additionally, rat
models treated with high doses of CRH developed cortico-
troph hyperplasia (11, 12). Therefore, multiple lines of evidence
indicate that chronic and excessive hypothalamic hormone
stimulation can result in increased pituitary hormone secretion
and cell proliferation, leading to tumor development and
neoplastic transformation in the adenohypophysis (13).
In dogs with PDH, the findings have been somewhat
conflicting, with different studies reporting hyposecretion,
normal secretion or hypersecretion of ACTH in response to
CRH. However, dogs with PDH generally exhibit a persis-
tent response to CRH, with elevated ACTH (14-16).DOI: 10.6061/clinics/2017(09)09
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BASIC RESEARCH
Considering the above evidence of the role of CRH and its
receptor CRHR1 in pituitary tumor development and the
high incidence of PDH in poodle dogs, our aim was to screen
for CRHR1 germline mutations in poodles with PDH.
’ MATERIALS AND METHODS
Animals
This prospective observational study included dogs that
were initially evaluated at the Veterinary Medical Teach-
ing Hospital of the University of Guarulhos from April
2006 through September 2007. All dogs were enrolled in
the study with the informed consent of their owners. The
possibility of PDH was based on historical data and a
physical examination.
The inclusion criteria were that each dog must have had at
least two clinical signs identified by the owner (polyuria,
polydipsia, polyphagia or abdominal enlargement) and at
least 2 of the following 6 clinicopathological findings: high
serum alkaline phosphatase activity, high serum alanine
aminotransferase activity, hypercholesterolemia, hypertrigly-
ceridemia, urine specific gravityo1.020, and thrombocytosis
(1, 4). All dogs underwent abdominal ultrasonography. For
each dog, the results of a low-dose dexamethasone suppres-
sion test (LDDST) were consistent with hyperadrenocorticism
(serum cortisol concentrations 8 hours after dexamethasone
treatmentX1.4 mg/dL). The diagnostic criteria for PDH inclu-
ded the following: an LDDST result indicative of spontaneous
hyperadrenocorticism, ultrasonographic evidence of bilateral
adrenal enlargement showing 2 relatively equal-sized, homo-
geneous adrenal glands and the absence of an adrenal mass,
and plasma concentration of endogenous ACTH417 pg/mL
(17, 18).
Computed tomography (CT) and magnetic resonance
imaging (MRI) were not performed due to the cost of these
examination, the need for anesthesia and because none of
the dogs had signs of neurological conditions or suspicion of
pituitary macroadenoma.
All dogs with concurrent disorders were excluded from
the study, as were those with an incomplete diagnosis of PDH,
those with adrenal-dependent hyperadrenocorticism suspi-
cion, and those that recently underwent PDH treatment.
Endocrine tests and hormone assays
For the LDDST, blood samples (2 mL each) were collected
before and 8 hours after IV administration of 0.01 mg/kg
dexamethasone to determine the serum concentrations of
cortisol. A serum cortisol concentration X1.4 mg/dL at
8 hours after dexamethasone administration was considered
consistent with naturally occurring hyperadrenocorticism (2).
Serum cortisol measurements were performed at the PROVET
Hormone Laboratory in São Paulo, Brazil. A radioimmunoas-
say was performed using a solid-phase commercial diagnostic
kit for cortisol (Coat-A-Count, Siemens Medical Solutions
Diagnostics, Malvern, PA, USA) that was previously validated
for canine cortisol (19). The intra-assay and inter-assay
coefficients of variation for cortisol were o5.1% and o6.4%,
respectively.
Plasma samples for ACTH measurements were collected
in plastic tubes containing EDTA and immediately refriger-
ated. The samples were transported to the laboratory inside
a Styrofoam container with ice for a maximum period of
1h before subsequent centrifugation at 1600 g for 15 min at
4oC. The samples were stored at -70oC until the assay was
performed. Plasma samples were collected over 18 months
and measured using 10 assays. Plasma ACTH concentrations
were measured using an immunoradiometric assay (IRMA)
with a commercial kit (ELSA-ACTH, CisBio International,
Codolet, France). The ACTH intra-assay and inter-assay
coefficients of variation according to the manufacturer were
o6.1% and o5.3%, respectively; the intra-assay and inter-
assay coefficients obtained in the laboratory were o7.8%
ando9.9%, respectively. Plasma ACTH measurements were
performed at the Hormone and Molecular Genetics Labora-
tory of Clinics Hospital, School Medicine, University of São
Paulo, Brazil. We used a human ACTH kit due to the lack of
a specific kit for dogs and because the ACTH molecule is
highly homologous between these two species.
The control group comprised 50 healthy poodles, includ-
ing 32 females and 18 males with a mean age of 9.4±
2.8 years (range, 6 to 16 years), which presented to the
Veterinary Teaching Hospital for ophthalmopathies, skin
lesions or elective castration. Control dogs were matched
to PDH dogs according to age (X6 years) and breed.
The criteria for inclusion in the control group were that
each dog was healthy, not obese, and presenting with
no clinical signs suggestive of hyperadrenocorticism and
with normal routine biochemical tests (urea, creatinine,
alanine aminotransferase, alkaline phosphatase) and
hemogram.
CRHR1 sequencing and analysis. Genomic DNA was
extracted from peripheral blood leukocytes that were obtained
from the 50 PDH and 50 control poodles using standardized
protocols (20). The CRHR1 coding region and intron-exon
junctions (GenBank NC_006591.3) were amplified by PCR
in an automated thermal cycler (Applied Biosystems PCR
System 9700) using specific primers. The PCRs were per-
formed with 2 mL of genomic DNA in a 50-mL final volume
that contained 200 mM dNTPs, 0.5 mM (20 pmol) primers,
1.5 U of GoTaq Polymerase (Promega Corporation, Madison,
WI, USA), 10 mL of 5x PCR reaction buffer (Promega),
1.5 mM MgCl2 and 0.4 M betaine. The PCR programs
included an initial activation at 98oC for 5 min followed by 40
cycles of 45 s at 98oC, 30 s at 50-58oC (depending on the
primers) and 45 s at 72oC, with a final extension at 72oC for
5 min. The final extension step for larger fragments, namely
exons 6-8 (993 bp) and 9-12 (1,235 bp), was 72oC for 3 min.
The products were visualized on a 1.5% agarose gel con-
taining ethidium bromide.
Eight pairs of intron-flanking primers were designed
based on the intron/exon structure of the CRHR1 gene using
the Primer3 core program. Exons 6 to 8 and exons 9 to 12
were amplified as single fragments (Table 1).
The resulting amplified products were purified and
subjected to capillary electrophoresis in an automatic ABI3100
Genetic Analyzer (Applied Biosystems). The resulting sequences
were compared with the CRHR1 reference sequence and
published on the NCBI website under Ensembl accession
number ENSCAFT00000021552.
CRHR1 allelic variant analysis by restriction enzyme
digestion. The allelic variant in exon 4 (codon 97) of the
CRHR1 gene eliminates a BstUI cleavage site. To identify this
variant in the control group, we performed enzymatic diges-
tion. Digestion reactions were performed on all samples in
the control group.
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Molecular modeling of CRHR1. A homology model for
the mutant canine CRHR1 was constructed based on an
available crystal structure (PDB ID: 3EHT), which includes
the human extracellular domain of CRHR1 bound to the
CRH peptide template (21), using YASARA (22). The p.V97M
mutant complex was constructed by superimposing the
modeled structure of the mutant canine CRHR1 over the
structure of the wild-type human CRHR1-CRH complex.
To assess whether the mutation interferes with ligand-
receptor binding, structure optimization was performed by
energy minimization to estimate the binding energy between
the hormone and the receptor. The binding energy was calcu-
lated using YASARA (See: http://www.yasara.org) with the
YAMBER3 force field (22).
In vitro studies. Plasmid construction: The human
CRHR1 cDNA sequence in the pcDNA plasmid was pur-
chased from LabLife (Cambridge, MA, USA). The plasmid
was mutagenized using specific primers (sense, 50-CTGGG
CCGCCCGCATGAATTACTCCG-30 and anti-sense, 50-CGGA
GTAATTCATGCGGGCGGCCCAG-30) with the QuikChange
Mutagenesis Kit (Stratagene, La Jolla, CA, United States),
according to the manufacturer’s instructions. The presence of the
mutagenic insertion was confirmed by automated sequencing
using a pcDNA primer (50-TAGAAGGCACAGTCGAGG-30).
Cell culture: AtT20 cells were grown in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen) and 1x
antibiotics (Invitrogen) at 37oC with 5% CO2. The AtT20 cells
were seeded at a density of 5x104 cells per well in 24-well
plates 1 day before transfection. The cells were transfected
with 1,000 ng/well of plasmid DNA. The empty pcDNA
vector was used to reach the total amount of plasmid per
well.
Transient transfection: In each well, 1 mg of DNA was
diluted in 150 mM NaCl to a final volume of 50 mL, and 2 mL
of jetPEI reagent was diluted separately in 150 mM NaCl to a
final volume of 50 mL. These 2 reagents were mixed and
incubated for 20 min at room temperature. The jetPEI/DNA
mixture (100 mL) was added to AtT20 cells that were seeded
in 500 mL of serum-containing medium; the transfection
reagent and medium were homogenized by gently swirling
the plate. The transfected cells were incubated in a cell
culture incubator for 24h. The cells were then washed 3 times
with PBS, and 100 nM human CRH (hCRH; Ferring) was
added to each well. Aliquots (10 mL) of the supernatant
media were collected from transfected AtT20 cells for ACTH
measurement 6, 12 and 24h after hCRH addition. The assays
were performed twice in triplicate. The ACTH levels in
media from transiently transfected mutant and wild-type
cells were expressed in terms of the fold change over the
basal ACTH level in non-stimulated cells that were trans-
fected with empty vector.
Statistical analysis
Analysis of variance (ANOVA) followed by Bonferroni’s
adjustment was used to compare the normalized fold change
in ACTH among groups at each time point. The data were
analyzed using Sigma Stat 3.5 software. Statistical signifi-
cance was set at po0.05.
’ RESULTS
Demographic and general characteristics of the
animals
The study included 50 consecutively selected poodles with
PDH, including 33 females and 17 males with a mean age of
8.7±2.8 years (range, 1.5 to 14 years), which presented at the
Veterinary Hospital of Guarulhos University. Among the
50 dogs, 3 had family members that were also affected by
PDH. The initial laboratory screening tests consisted of
determining the serum levels of cholesterol, triglycerides,
alkaline phosphatase, and alanine aminotransferase as well
as tests for glycemia, urinary density, dexamethasone sup-
pression, and abdominal ultrasonography.
Hypercholesterolemia and hypertriglyceridemia were found
in 78% (n=39/50) and 74% (n=37/50) of the cases, respec-
tively, with mean cholesterol values of 396 ± 156 mg/dL
and triglycerides of 169±96 mg/dL. Elevated blood levels
of alkaline phosphatase and alanine aminotransferase were
observed in 78% (n=39/50) of the cases (mean value 459±
401 IU/L) and in 70% (n=35/50) of the cases (mean value
204±158 IU/L), respectively. Urinary densities below the
reference values (1.025–1.045) were identified in 80% of the
animals (n=40/50), of which 20% (n=10/50) showed hypo-
sthenuria (densityp1008). Hyperglycemia was identified in
six animals (12%), two of which were insulin-dependent
diabetics.
No animals showed suppression of serum cortisol levels
8 hours after the intravenous application of dexamethasone
(mean values of cortisol=5.4±3.3 mg/dL), confirming endo-
genous hypercortisolism. All cases were diagnosed with
PDH based on ACTH baseline plasma concentrations above
17 pg/mL (mean values of ACTH=42±30 pg/mL).
Abdominal ultrasound showed symmetric adrenal glands
with regular contours, homogeneous echotextures, and the
absence of nodulations and calcifications. The mean values of
the caudal pole thickness of the right and left adrenal glands
were 0.73±0.14 and 0.74±0.11 cm, respectively. Dogs with
pituitary-dependent hypercortisolism have, on average, a
caudal pole thickness greater than or equal to 0.7 cm (23).
Mutation analysis
We identified only one heterozygous variant in one of the
dogs with PDH, in exon 4 of the CRHR1 gene. This variant
results from a guanine-to-adenine (G- A) change in codon
Table 1 - Forward (F) and reverse (R) primers for canine CRHR1
amplification, with product sizes (bp) and annealing
temperatures (Ta).
Primer Sequence Product size (bp) Ta (
oC)
1F 50 CTGAGTCAGGAGACGGCGCA 30 422 50
1R 50 TCATTGTGGCGAAGCTGCTG 30
2F 50 TTGGGATCCTAGGCTTGATG 30 413 58
2R 50 GCAAGATTCCAGGTCTCCAG 30
3F 50 GAACGAATGCTGGATCCCTA 30 456 50
3R 50 TCTCGTGGATACAACCAC 30
4F 50 AGATGGACGAACCAATGGAC 30 581 58
4R 50 AGTCTCCTTCCCACCCTGTC 30
5F 50 GGGAAGGGGAATAACTACCG 30 401 50
5R 50 GTCTCTTGGAACCTCTGGCA 30
6-8F 50 TCCTCAGTTTCCCCATCCATA 30 993 50
6-8R 50 TGAGGTACAGGCTCTCAGCC 30
9-12F 50 GAGGCATTGTGTTGGGATCT 30 1,235 55
9-12R 50 CAGGTCCCTAATGAGGATGC 30
13F 50 ACGTGTACTGCTGCTTGTGG 30 419 58
13R 50 GAGAGCAGCCATAGTCTGGG 30
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97 that causes a valine-to-methionine substitution (p.V97M)
(Figure 1). Although both valine (encoded by GTG) and
methionine (encoded by ATG) are nonpolar amino acids, the
Val97 residue is highly conserved among different species.
According to BLAST (https://blast.ncbi.nlm.nih.gov/Blast.
cgi), the coding region of CRHR1 is 98% similar between
dogs and humans, and the protein shares the same amino
acid, valine, at position 97. Moreover, this change occurred in
the amino-terminal portion of the extracellular domain of the
CRHR1 receptor, which has a high affinity for the ligand (22).
The p.V97M allelic variant was not found among the
100 poodle alleles in the control group or in the normal
siblings of the disease cases. The animal with the p.V97M
allelic variant was 9 years old and had a history suggestive of
hypercortisolism for at least 12 months. The dog showed
clinical features of hyperadrenocorticism, suggesting chronic
and progressive disease (Figure 2). The serum cortisol level
after an intravenous injection of dexamethasone was 7.8 mg/dL,
and his baseline plasma ACTH level (45 pg/mL) confirmed
the presence of ACTH-dependent hypercortisolism. An abdo-
minal ultrasound examination revealed thickening of the
caudal poles of the right (1.0 cm) and left (0.92 cm) adrenal
glands, both of which showed regular contours, homo-
geneous echotexture and reduced echogenicity.
The animal was treated with mitotane at a dose of 25 mg/kg
every 12h for 7 days (induction phase); subsequently, it was
treated with 25 mg/kg twice a week (maintenance phase).
At this time, trilostane, which is currently considered the first
choice of drug in canine PDH therapy, was not available
in Brazil. The animal showed partial improvement, with
several adjustments of the mitotane dose being necessary
during the 10-months of follow-up therapy. For personal and
financial reasons, the owner discontinued the treatment. The
animal died 6 months after the treatment was discontinued,
likely due to pulmonary embolism.
The affected dog’s male offspring is not a carrier of the
p.V97M mutation and did not shown symptoms of Cush-
ing’s disease at 7 years of age.
Mutant protein modeling study
The allelic variant p.V97M is located in the extracellular
amino terminus of the CRHR1 protein, which is considered
the primary region for receptor-ligand binding (21, 24). Protein
modeling revealed that relative to the wild-type protein, the
CRHR1 mutant showed a 17% increase in its binding affinity
for CRH. Changes in the 3-dimensional structure of the extra-
cellular domain of CRHR1 affect receptor activation and
affinity for the ligand (21, 25).
The quaternary structures of the mutant and wild-type
proteins were examined, and the binding energy between the
hormone and its receptors was evaluated to better under-
stand the involvement of this variant in the pathogenesis of
ACTH-dependent hyperadrenocorticism. A comparison of
the 3-dimensional structures of the complexes formed with
the mutant (p.V97M) and wild-type proteins revealed a
structural rearrangement in the contact surface between the
p.V97M receptor and the ligand (Figure 3).
To assess whether the mutation interferes with receptor-
ligand binding, optimization of the mutant complex struc-
ture was performed using energy minimization. The binding
energy between the hormone and the receptor was then
estimated.
The binding enthalpy was 1,893 kJ/mol for the wild-type
complex and 2,134 kJ/mol for the p.V97M complex; the
mutant CRHR1 exhibited a 17% increase in its binding
affinity for CRH, therefore suggesting a clear gain of function
for the p.V97M variant.
Functional characterization of the CRHR1 mutant
protein
The fold changes in the ACTH levels after stimula-
tion relative to the basal levels in AtT20 cells transfected
with empty, wild type and mutant vectors were 5.01±0.65,
5.41±0.57 and 11.57±1.45, respectively, at 12 h and 14.0±
1.72, 21±3.6 and 38.9±0.45, respectively, at 24h. There was a
significant increase in the ACTH levels in the mutant relative
to the wild-type at 12 h (*po0.05) and 24 h (**po0.01)
(Figure 4).
’ DISCUSSION
The expression of CRHR1 in human corticotrophinomas
suggests that hormone receptors play a role in pituitary tumori-
genesis, promoting sustained cell stimulation even in the absence
of hypothalamic hormones (26-28). Corticotroph tumors in
dogs and humans exhibit CRHR1 overexpression and greater
sensitivity to CRH (13, 29, 30).
In the present study, we screened the CRHR1 gene for
mutations in poodles with PDH and identified 1 dog with a
novel p.V97M activating heterozygous allelic mutation that
was located at the amino-terminal portion of the extracellular
domain of CRHR1. The p.V97M CRHR1 mutant has a larger
Figure 1 - The wild-type sequence of exon 4 of the CRHR1 gene
from a control dog (upper panel) and the heterozygous G-to-A
substitution causing the amino acid change (p.V97M) in a poodle
with ACTH-dependent hypercortisolism (lower panel).
Figure 2 - The dog with ACTH-dependent hypercortisolism and
carrying the allelic variant p.V97M, showing marked abdominal
distension, alopecia, skin atrophy and telangiectasia.
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apolar surface created by the methionine side chain, which
may increase the van der Waals contacts with the Ile41 residue
of CRH and thus favor ligand binding. Optimization of
the molecular and quaternary structure of this mutated pro-
tein by energy minimization indicated the existence of a
structural rearrangement due to an altered contact surface
between the mutated receptor and the ligand. In vitro stu-
dies revealed that AtT20 cells transfected with the mutant
plasmid over-secreted ACTH compared relative to cells
transfected with the wild-type plasmid. The maximal effects
Figure 3 - The structural rearrangement in the mutant protein (red) and the resulting changes in the contact surface between the
ligand and the mutant receptor (containing methionine). The wild-type receptor is shown for comparison.
Figure 4 - The observed fold changes in ACTH relative to the basal ACTH level in cells transfected with empty vector were 5.01±0.65
(empty vector, EV), 5.41±0.57 (wild-type, WT) and 11.57±1.45 (mutant, MUT) at 12h and 14.0±1.72 (EV), 21±3.6 (WT) and 38.9±0.45
(MUT) at 24h. There were significant differences in the ACTH levels of cells transfected with the mutant plasmid compared with cells
transfected with the wild-type plasmid or with empty vector at 24h (**po0.01, *po0.05).
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of the mutant and wild-type plasmids on hormone release
were observed after 24 h of hCRH stimulation, which caused
approximately 38.9- and 21-fold increases in ACTH levels,
respectively, over the basal levels in cells transfected with
empty vectors. This result confirmed that the variant is an
activating mutation.
Changes in the 3-dimensional structure of the extracellular
domain of CRHR1 affect the activation of the receptor and its
affinity for the ligand (21, 24, 31, 32).
The binding of CRH to CRHR1 ligand-binding sites has
been extensively investigated in studies of chimeric recep-
tors. These studies have indicated that residues 1-118 of the
N-terminal domain (specifically, amino acid residues 43-50
and 76-84 in humans and 68-109 in mice) are the most
important regions for agonist binding (33-36).
Pioszak, Parker (21) reported the importance of valine 97
(Val97) for interactions between CRHR1 and CRH. This
interaction occurs through 2 intermolecular hydrogen bonds
between the oxygen and nitrogen atoms of the amide
C-terminal ligand (CHR) and the amidic nitrogen atoms and
carbonyl oxygen of the main chain of the receptor (residue
Val97).
Optimization of the molecular and quaternary structure of
the mutant protein by energy minimization indicated the
occurrence of a structural rearrangement due to an altered
contact surface between the mutant receptor and the ligand.
The p.V97M CRHR1 mutant has a larger apolar surface that
is created by the methionine side chain, which may increase
van der Waals contacts with the Ile41 residue of CRH to
favor binding. Additionally, the prediction that the surface
binding energy is increased between the ligand (CRH) and
the mutant receptor (CRHR1m) supports the hypothesis
that this activating mutation in CRHR1 is involved in the
pathogenesis of PDH in this poodle. The late onset of PDH in
this animal may contradict the notion that the disease has a
genetic etiology; however, other model germline disorders
that present later in life, including retinitis pigmentosa and
multiple endocrine neoplasia, are well accepted (37, 38). In
the affected poodle, the increased ACTH stimulation and
secretion caused by the increased affinity of the mutant
CRHR1 for CRH might have taken several years to promote
corticotroph hyperplasia. Unfortunately, this possibility remains
untested, as neither skull magnetic resonance (to visualize the
pituitary mass) nor animal necropsy (to identify corticotroph
hyperplasia or neoplasia) was performed.
Thyrotropin receptors (TSHRs) have been widely studied as
models for activating mutations, which are located not only
in the transmembrane region but also in the amino-terminal
extracellular domain (39). Cases of non-autoimmune congenital
hyperthyroidism have been reported as secondary to de novo
germline mutations in the TSHR extracellular domain in
humans (40). In addition to the influence of the extracellular
amino-terminal domain of GPCRs on receptor-ligand binding
affinity, this domain might also act as an internal antagonist
that is capable of having agonist or antagonist properties
depending on whether it is bound to the ligand (39).
Although the monoclonal origin of pituitary adenomas has
been well established since 1990, there have been instances in
which the monoclonal character was acquired at a later stage
of polyclonal growth (41). Schulte, Oldfield (42) demon-
strated that corticotroph adenomas of the pituitary gland
might arise from a single cell or from more than one cell,
making them monoclonal or polyclonal in origin. These
observations are compatible with the idea of an initiating
stimulus that causes hyperplasia of specific cell types in the
pituitary, itself giving rise to several distinct clones with
variable potential to develop into tumors. Such stimuli may
include hypothalamic trophic factors, intrapituitary growth
factors or pituitary-specific oncogenes (43).
Another hypothesis is that the affected dog, by carrying a
CRHR1 activating mutation, developed only pituitary hyper-
plasia and not an adenoma. Pituitary hyperplasia and
pituitary adenoma are both possible explanations for the
ACTH over-secretion and chronic hypercortisolism observed
in this dog.
This study aimed to investigate whether Cushing’s disease
in poodles has a genetic origin. We found only one dog with
an activating mutation among 50 poodles with hyper-
adrenocorticism, which indicated that in most of cases, the
mutation did not cause Cushing’s disease. However, taking
into account the high similarity of CRHR1 between humans
and dogs, our data suggest that this mutation may also be
involved in some human cases of Cushing’s disease; thus,
these results may be clinically relevant.
The limitations of this study included the unavailability of
tumor tissues and the availability of only one male offspring
from the dog with the allelic variant p.V97M to test for
segregation.
In conclusion, we reported a mutation in CRHR1 that leads
to persistent activation of the receptor in a poodle with
ACTH-dependent hyperadrenocorticism, indicating that this
is a rare cause of ACTH-dependent hyperadrenocorticism.
This new finding, although rare, suggests that other germline
mutations that activate the hypothalamus-pituitary-adrenal
axis may be associated with this phenotype in dog breeds
commonly affected by ACTH-dependent hyperadrenocorticism.
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